Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Severe Major Depression With Psychotic Features

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Severe Major Depression With Psychotic Features. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-002156-34 Sponsor Protocol Number: 28133 Start Date*: 2005-06-14
    Sponsor Name:NV Organon
    Full Title: Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episo...
    Medical condition: Psychotic major depression (major depressive episode, severe, with psychotic features)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037250 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-000050-23 Sponsor Protocol Number: 28130 Start Date*: 2004-09-15
    Sponsor Name:NV Organon
    Full Title: Prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic major de...
    Medical condition: Psychotic major depression (major depressive episode, severe, with psychotic features)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037250 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000041-60 Sponsor Protocol Number: D1443L00040 Start Date*: 2008-06-17
    Sponsor Name:LWL Universitätsklinik für Psychiatrie Bochum
    Full Title: Quetiapine in the treatment of psychotic depression. A pilot study (QTP-Dep-Bo)
    Medical condition: The planned open and monocentric trial investigates quetiapine as a monotherapy for patients with unipolar depression and psychotic features. The aim of this pilot study is to investigate the antid...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012393 Depression psychotic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001361-32 Sponsor Protocol Number: 14571A Start Date*: 2013-04-29
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in el...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.1 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.1 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.1 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) EE (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001380-76 Sponsor Protocol Number: 14570A Start Date*: 2013-03-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    18.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    18.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    18.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    18.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) FI (Completed) LT (Completed) GB (Completed) BG (Completed) IT (Prematurely Ended) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-004169-42 Sponsor Protocol Number: 14767B Start Date*: 2013-08-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025463 Major depressive disorder, single episode LLT
    16.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    16.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    16.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    16.0 100000004873 10025457 Major depressive disorder, recurrent episode, mild degree LLT
    16.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    16.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004030-28 Sponsor Protocol Number: EKFADHTC01032017 Start Date*: 2018-09-10
    Sponsor Name:Psychiatric Research Unit
    Full Title: Cognition and weight gain during antidepressant treatment.
    Medical condition: Major Depressive Disorder.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012375 Depressed mood disorders and disturbances HLGT
    20.0 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    20.0 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    20.0 10037175 - Psychiatric disorders 10025467 Major depressive disorder, single episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    20.0 10037175 - Psychiatric disorders 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    20.0 10037175 - Psychiatric disorders 10025463 Major depressive disorder, single episode LLT
    20.0 10037175 - Psychiatric disorders 10025454 Major depressive disorder, recurrent episode LLT
    20.0 10037175 - Psychiatric disorders 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    20.0 10037175 - Psychiatric disorders 10025456 Major depressive disorder, recurrent episode, in partial or unspecified remission LLT
    20.0 10037175 - Psychiatric disorders 10067465 Major depressive disorder aggravated LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003190-29 Sponsor Protocol Number: HMNC-101 Start Date*: 2012-01-30
    Sponsor Name:HolsboerMaschmeyer NeuroChemie (HMNC) GmbH
    Full Title: Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene
    Medical condition: - Major Depression, single or recurrent, without psychotic features - Bipolar Disorders, currently depressed, without psychotic features
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    14.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016715-38 Sponsor Protocol Number: TEAprotocolversion3-12102009FINAL Start Date*: 2010-02-08
    Sponsor Name:University of Copenhagen
    Full Title: The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and...
    Medical condition: non-organic and non-drug-induced psychosis, meeting the criteria for ICD-10 diagnoses: F20, F22-F29 and F30.2, F31.2, F31.5, F32.3 and F33.3.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10032314 Other nonorganic psychoses LLT
    16.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    16.1 10037175 - Psychiatric disorders 10004916 Bipolar affective disorder, depressed, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10025460 Major depressive disorder, recurrent episode, severe degree, specified as with psychotic behaviour LLT
    16.1 10037175 - Psychiatric disorders 10039621 Schizoaffective disorder PT
    16.1 10037175 - Psychiatric disorders 10025468 Major depressive disorder, single episode, severe degree, specified as with psychotic behavior LLT
    16.1 10037175 - Psychiatric disorders 10046122 Unspecified psychosis LLT
    16.1 10037175 - Psychiatric disorders 10026780 Manic psychosis LLT
    16.1 10037175 - Psychiatric disorders 10012255 Delusional disorder, unspecified type PT
    16.1 10037175 - Psychiatric disorders 10051988 Acute and transient psychotic disorder LLT
    16.1 10037175 - Psychiatric disorders 10004924 Bipolar affective disorder, manic, severe degree, specified as with psychotic behavior LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003867-13 Sponsor Protocol Number: CL2-47445-014 Start Date*: 2016-02-15
    Sponsor Name:Institut de Recherches internationales Servier
    Full Title: Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, pla...
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000439-22 Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 Start Date*: 2023-03-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) BE (Completed) BG (Completed) PT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001618-34 Sponsor Protocol Number: 1208.24 Start Date*: 2006-12-11
    Sponsor Name:BOEHRINGER ING.
    Full Title: An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression
    Medical condition: Treatment of severely depressed patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003658-47 Sponsor Protocol Number: F02207 GE 3 03 Start Date*: 2006-11-21
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-005149-64 Sponsor Protocol Number: MIN-117C03 Start Date*: 2018-05-23
    Sponsor Name:Minerva Neurosciences, Inc
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016463-10 Sponsor Protocol Number: AROT-2009 Start Date*: 2010-03-18
    Sponsor Name:LWL University Hospital Bochum
    Full Title: Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial
    Medical condition: Major Depression
    Disease: Version SOC Term Classification Code Term Level
    12.0 10057840 Major depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003981-13 Sponsor Protocol Number: CL3-20098-041 Start Date*: 2004-12-16
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agome...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004780-34 Sponsor Protocol Number: A7571001 Start Date*: 2006-04-18
    Sponsor Name:Pfizer Ltd, Sandwich, UK
    Full Title: An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients w...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10025454 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004008-19 Sponsor Protocol Number: CL3-20098-045 Start Date*: 2005-08-23
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    3. SERVIER Research and Development ICTR (For United Kingdom only)
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel...
    Medical condition: Severe Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-000461-41 Sponsor Protocol Number: 67953964MDD3002 Start Date*: 2023-02-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) FR (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004009-10 Sponsor Protocol Number: CL3-20098-046 Start Date*: 2005-06-29
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind inte...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10025453 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 08:03:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA